EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells

Cancer Letters
Chao YangChunsheng Kang


EGFR amplification and mutations are the most common oncogenic events in GBM. EGFR overexpression correlates with GBM invasion, but the underlying mechanisms are poorly understood. In a previous study, we showed that AJAP1 is involved in regulating F-actin to inhibit the invasive ability of GBM. In addition, in a GBM cell line, the AJAP1 promoter was highly bound by H3K27me3 and, through bioinformatics analysis, we found that AJAP1 expression was negatively correlated with EGFR. In this study, we found that the pathway downstream of EGFR had a higher activation level in GBM cell lines, which led to excessive tumor suppressor silencing. Therefore, we deduced that in glioma cells, the pathway downstream of EGFR remodels the cytoskeleton via AJAP1 epigenetic silencing to enhance invasion. Furthermore, MK2206 reversed AJAP1 downregulation by inhibiting the EGFR pathway. In vivo, MK2206 also inhibited the proliferation and local invasion of 87-EGFRvIII. These data suggest that activation of the EGFR signal transduction pathway genetically silences anti-oncogenes to enhance GBM malignancy. MK2206 might be a promising therapeutic for EGFR/EGFRvIII-positive GBMs.


Jan 1, 1992·Journal of Neuropathology and Experimental Neurology·M R HurttJ Locker
Jun 1, 2002·Science·Lewis C Cantley
Sep 18, 2004·Cancer Research·William A FreijeStanley F Nelson
Feb 3, 2005·Acta Neuropathologica·Hiroko Ohgaki, Paul Kleihues
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Nov 12, 2005·The New England Journal of Medicine·Ingo K MellinghoffPaul S Mischel
Nov 3, 2007·Genes & Development·Frank B FurnariWebster K Cavenee
May 10, 2008·Nature Reviews. Molecular Cell Biology·Pieta K Mattila, Pekka Lappalainen
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Jul 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Deliang GuoPaul S Mischel
Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
May 4, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria E BalasisSaïd M Sebti
Jan 14, 2012·Molecular Cancer Research : MCR·Ningjing LinDavid Cory Adamson
Aug 14, 2013·Annual Review of Pathology·Timothy F CloughesyPaul S Mischel
Oct 15, 2013·Cell·Cameron W BrennanUNKNOWN TCGA Research Network
Mar 12, 2016·Cancer Letters·Tao JiangUNKNOWN Chinese Glioma Cooperative Group (CGCG)
Aug 1, 2016·Trends in Neurosciences·Frédéric A Meunier, Luis M Gutiérrez

❮ Previous
Next ❯


Jun 7, 2019·Journal of Experimental & Clinical Cancer Research : CR·Cong XuYun Niu
Jan 30, 2020·Clinical and Translational Medicine·Hongyu ZhaoLiang Zeng
Oct 17, 2021·Journal of Clinical Laboratory Analysis·Rubing LiFeng Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.